These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 19496633)

  • 21. Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial.
    Cohen C; Nieto-Cisneros L; Zala C; Fessel WJ; Gonzalez-Garcia J; Gladysz A; McGovern R; Adler E; McLaren C;
    Curr Med Res Opin; 2005 Oct; 21(10):1683-92. PubMed ID: 16238909
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical utility of atazanavir].
    Ribera Pascuet E; Curran A
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():55-67. PubMed ID: 20116619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy, tolerability and virological consequences of long-term use of unboosted atazanavir plus 2 NRTIs in HIV-infected patients.
    Bonora S; Calcagno A; Vigano O; Bigliano P; Marinaro L; Colella E; Orofino G; Trentini L; Tettoni MC; D'Avolio A; Mercadante S; Galli M; Di Perri G; Rusconi S
    Curr HIV Res; 2014; 12(5):339-46. PubMed ID: 25106410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
    Pavie J; Porcher R; Torti C; Medrano J; Castagna A; Valin N; Rusconi S; Ammassari A; Ghosn J; Delaugerre C; Molina JM;
    J Antimicrob Chemother; 2011 Oct; 66(10):2372-8. PubMed ID: 21821627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cumulative exposure to ritonavir-boosted atazanavir is associated with cholelithiasis in patients with HIV-1 infection.
    Nishijima T; Shimbo T; Komatsu H; Hamada Y; Gatanaga H; Kikuchi Y; Oka S
    J Antimicrob Chemother; 2014 May; 69(5):1385-9. PubMed ID: 24379301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Efficacy of atazanavir in rescue therapy].
    Portilla J; Boix V; Merino E; Reus S
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():22-7. PubMed ID: 20116613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atazanavir: in pediatric patients with HIV-1 infection.
    Deeks ED
    Paediatr Drugs; 2012 Apr; 14(2):131-41. PubMed ID: 22292486
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in kidney function in patients with suppressed HIV RNA who substitute their protease inhibitor with atazanavir/ritonavir.
    Hamzah L; Campbell L; Wandolo E; Engler B; Cheserem E; Naftalin C; Taylor C; Post FA
    AIDS; 2015 Jan; 29(3):392-4. PubMed ID: 25686688
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
    Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
    J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atazanavir: a new protease inhibitor to treat HIV infection.
    Musial BL; Chojnacki JK; Coleman CI
    Am J Health Syst Pharm; 2004 Jul; 61(13):1365-74. PubMed ID: 15287232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is ritonavir-boosted atazanavir a risk for cholelithiasis compared to other protease inhibitors?
    Hamada Y; Nishijima T; Komatsu H; Teruya K; Gatanaga H; Kikuchi Y; Oka S
    PLoS One; 2013; 8(7):e69845. PubMed ID: 23875004
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in body composition with ritonavir-boosted and unboosted atazanavir treatment in combination with Lamivudine and Stavudine: a 96-week randomized, controlled study.
    McComsey G; Rightmire A; Wirtz V; Yang R; Mathew M; McGrath D
    Clin Infect Dis; 2009 May; 48(9):1323-6. PubMed ID: 19302017
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir.
    Laker EAO; Nabaggala MS; Kaimal A; Nalwanga D; Castelnuovo B; Musubire A; Kiragga A; Lamorde M; Ratanshi RP
    BMC Infect Dis; 2019 Mar; 19(1):280. PubMed ID: 30909871
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Safety of atazanavir in patients with HIV and hepatitis B and/or C virus coinfection].
    Rivero A; Camacho A; Pérez-Camacho I; Torre-Cisneros J
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():45-8. PubMed ID: 20116617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Oldfield V; Plosker GL
    Drugs; 2006; 66(9):1275-99. PubMed ID: 16827606
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Insulin resistance in HIV-infected patients receiving long-term therapy with efavirenz, lopinavir/ritonavir and atazanavir].
    Bernal E; Masiá M; Padilla S; Ramos JM; Martín-Hidalgo A; Gutiérrez F
    Med Clin (Barc); 2007 Jul; 129(7):252-4. PubMed ID: 17683706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
    Perez-Molina JA; Rubio R; Rivero A; Pasquau J; Suárez-Lozano I; Riera M; Estébanez M; Santos J; Sanz-Moreno J; Troya J; Mariño A; Antela A; Navarro J; Esteban H; Moreno S;
    Lancet Infect Dis; 2015 Jul; 15(7):775-84. PubMed ID: 26062881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).
    Di Giambenedetto S; Fabbiani M; Colafigli M; Ciccarelli N; Farina S; Sidella L; D'Avino A; Mondi A; Cingolani A; Tamburrini E; Murri R; Navarra P; Cauda R; De Luca A
    J Antimicrob Chemother; 2013 Jun; 68(6):1364-72. PubMed ID: 23372058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.